Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$4.22 -3.2%	$3.96	$2.24 ▼ $19.69	$201.98M	2.81	762,705 shs	316,866 shs
JSPR Jasper Therapeutics	$3.33 -1.2%	$5.04	$2.27 ▼ $26.05	$50.62M	2.69	402,281 shs	349,166 shs
NLTX Neoleukin Therapeutics	$22.34 -1.2%	$19.01	$2.03 ▼ $14.36	$209.95M	1.11	50,104 shs	111,114 shs
NMRA Neumora Therapeutics	$1.85 +8.2%	$0.88	$0.61 ▼ $17.19	$276.59M	2.75	1.60 million shs	5.28 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	-3.21%	-1.40%	+3.18%	+37.91%	-76.81%
JSPR Jasper Therapeutics	-1.19%	-5.13%	-36.69%	-16.12%	-84.20%
NLTX Neoleukin Therapeutics	+0.27%	+6.30%	+22.69%	+96.69%	-49.03%
NMRA Neumora Therapeutics	+8.19%	+43.41%	+137.18%	+186.02%	-84.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FDMT 4D Molecular Therapeutics	2.2203 of 5 stars	3.3	3.0	0.0	0.0	1.2	1.7	0.6
JSPR Jasper Therapeutics	3.7384 of 5 stars	4.3	4.0	0.0	0.0	3.0	1.7	0.6
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	2.3843 of 5 stars	3.1	3.0	0.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	600.37% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$29.75	793.39% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
NMRA Neumora Therapeutics	2.22	Hold	$7.14	286.10% Upside

Current Analyst Ratings Breakdown

Latest JSPR, NMRA, FDMT, and NLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FDMT 4D Molecular Therapeutics	$40K	4,887.82	N/A	N/A	$11.05 per share	0.38
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)

Latest JSPR, NMRA, FDMT, and NLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/12/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.28	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
JSPR Jasper Therapeutics	N/A	4.31	4.31
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
NMRA Neumora Therapeutics	N/A	8.98	8.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FDMT 4D Molecular Therapeutics	99.27%
JSPR Jasper Therapeutics	79.85%
NLTX Neoleukin Therapeutics	52.37%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
FDMT 4D Molecular Therapeutics	9.60%
JSPR Jasper Therapeutics	4.60%
NLTX Neoleukin Therapeutics	1.58%
NMRA Neumora Therapeutics	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable

JSPR, NMRA, FDMT, and NLTX Headlines

Recent News About These Companies

Neumora Therapeutics (NASDAQ:NMRA) Given New $5.00 Price Target at Mizuho

July 16 at 8:37 AM | marketbeat.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

July 10, 2025 | finanznachrichten.de

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

July 9, 2025 | globenewswire.com

With 43% ownership, Neumora Therapeutics, Inc. (NASDAQ:NMRA) has piqued the interest of institutional investors

July 2, 2025 | finance.yahoo.com

Lunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA)

June 29, 2025 | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Analysts

June 26, 2025 | marketbeat.com

Neumora Therapeutics Inc News (NMRA) - Investing.com

June 24, 2025 | investing.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 27, 2025 | globenewswire.com

Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development

May 24, 2025 | uk.investing.com

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

May 14, 2025 | prnewswire.com

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finanznachrichten.de

Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...

May 13, 2025 | finance.yahoo.com

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?

May 11, 2025 | finance.yahoo.com

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 28, 2025 | globenewswire.com

Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Up 10.34%

April 23, 2025 | aaii.comA

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

April 16, 2025 | investing.com

Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating

April 9, 2025 | tipranks.com

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

April 8, 2025 | accessnewswire.comA

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline

April 7, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, NMRA, FDMT, and NLTX Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

$4.22 -0.14 (-3.21%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.22 0.00 (-0.12%)

As of 07/18/2025 06:16 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Jasper Therapeutics NASDAQ:JSPR

$3.33 -0.04 (-1.19%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.36 +0.04 (+1.05%)

As of 07/18/2025 07:43 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Neoleukin Therapeutics NASDAQ:NLTX

$22.34 -0.26 (-1.15%)

As of 07/18/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Neumora Therapeutics NASDAQ:NMRA

$1.85 +0.14 (+8.19%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.03 (+1.89%)

As of 07/18/2025 07:58 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time